Select Medications to Clinically Avoid in End-of-Life Care

Description

Free Webinar:

1 Hour Applied For

Register HERE!

At the end-of-life, patient pharmacokinetic and pharmacodynamic characteristics are extremely dynamic. Select medications require more vigilant monitoring as compared to others as renal and hepatic function decline. This presentation will aid hospice clinicians in developing and maintaining a working knowledge of emerging medication use issues involving the use of Empagliflozin (Jardiance), Dapaglifozin (Farxiga), Suzetrigine (Journavx) and other select medications used at the end-of-life.